Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013267 | 0.96 | ATM (0.59) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25223302 | 0.89 | HPGD (0.59) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15172000 | 0.89 | MEN1 (0.52) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30655523 | 0.88 | RAB9A (0.54) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1817008 | 0.87 | ALDH1A1 (0.58) | RAB9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4820908 | 0.86 | CES2 (0.69) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30414806 | 0.86 | MEN1 (0.69) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL755443 | 0.86 | MEN1 (0.69) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31020261 | 0.86 | CES2 (0.74) | HTTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3545138 | 0.86 | TUBB4A (0.68) | HTTNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462384-A | Pterostilbene derivatives and their use in preparing medicine for treating and/or preventing diseases caused by oxidative stress | 常州大学 | 2025-02-18 | — | — | CN | disclosed |
| EP-3688000-B1 | HYDROCARBON-SOLUBLE HALOGEN AND THIOLATE/MAGNESIUM EXCHANGE REAGENTS | ALBEMARLE GERMANY GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11236113-B2 | Hydrocarbon-soluble halogen and thiolate/magnesium exchange reagents | ALBEMARLE GERMANY GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239496-A1 | Hydrocarbon-Soluble Halogen and Thiolate/Magnesium Exchange Reagents | Ludwig-Maximilians-Universitat München (DE) | 2020-07-30 | — | — | US | disclosed |
| WO-2019063418-A1 | HYDROCARBON-SOLUBLE HALOGEN AND THIOLATE/MAGNESIUM EXCHANGE REAGENTS | ALBEMARLE GERMANY GMBH (DE) | 2019-04-04 | — | — | WO | disclosed |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| CN-107148453-A | Photocurable composition | 思美定株式会社 | 2017-09-08 | — | — | CN | disclosed |
| WO-2017030983-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| EP-1799634-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1603864-A4 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| CN-1780811-A | Diphenylethylene compounds and uses thereof | CELGENE CORP (US) | 2006-05-31 | — | — | CN | disclosed |
| WO-2006026747-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | HTT 1033/4885NPC1 789/4885RAB9A 4576/4885 |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | HTT 4838/4885NPC1 1681/4885RAB9A 3859/4885 |
| US-20200239496-A1 | Hydrocarbon-Soluble Halogen and Thiolate/Magnesium Exchange Reagents | OR10J3, MSRB3, SLC39A3 | HTT 2317/4885NPC1 2614/4885RAB9A 3066/4885 |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSS, CTSB, CTSK | HTT 1418/4885NPC1 419/4885RAB9A 169/4885 |
| US-11236113-B2 | Hydrocarbon-soluble halogen and thiolate/magnesium exchange reagents | MSRB3, OR10J3, GFER | HTT 2229/4885NPC1 2800/4885RAB9A 3314/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | HTT 1033/4885NPC1 789/4885RAB9A 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.